Short Interest in Mainz Biomed NV (NASDAQ:QUCY) Increases By 996.3%

Mainz Biomed NV (NASDAQ:QUCY) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 10,530,990 shares, a growth of 996.3% from the April 30th total of 960,587 shares. Based on an average daily volume of 79,673,861 shares, the days-to-cover ratio is currently 0.1 days. Approximately 79.6% of the shares of the company are sold short.

Analyst Ratings Changes

QUCY has been the topic of several analyst reports. Maxim Group downgraded Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce”.

Mainz Biomed Stock Performance

Shares of QUCY traded down $0.42 during mid-day trading on Friday, reaching $2.56. 4,018,985 shares of the company’s stock were exchanged, compared to its average volume of 10,712,514. Mainz Biomed has a 52-week low of $0.30 and a 52-week high of $4.93. The company has a market cap of $37.53 million, a P/E ratio of -0.05 and a beta of 0.42. The stock’s 50-day simple moving average is $1.13.

Mainz Biomed (NASDAQ:QUCY) last posted its earnings results on Tuesday, March 31st. The company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $0.13 million during the quarter.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.